Discover results from the ODYSSEY OUTCOMES trial conducted in post-acute coronary syndrome (ACS) patients testing
View alirocumab dose titration and the ODYSSEY OUTCOMES
treat-to-target approach
Learn about primary MACE and additional CV endpoints in the overall population
Learn about the results on MACE in high risk patients (baseline LDL-C ≥100 mg/dL)
Select ODYSSEY OUTCOMES publications
ODYSSEY OUTCOMES primary manuscript
Sub-analysis of the patients with and without diabetes
ACS=acute coronary syndrome; LDL-C low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; PCSK9=proprotein convertase subtilisin/kexin type 9.